Session Type
Date Time

The current HIV vaccine portfolio is both ambitious and filled with challenges. This session examines the most recent advances in prophylactic and therapeutic vaccine strategies designed to promote neutralization-independent mechanisms and elicit T cell responses with the potential to eradicate the virus.

SY09.01 Ad26 mosaic vaccine development program
Daniel STIEH, Johnson & Johnson, Netherlands
SY09.03 CMV-vectored vaccines for HIV prevention
Louis PICKER, Vaccine and Gene Therapy Institute, United States
SY09.04 Refocusing T cell responses with therapeutic vaccination strategies
Tom HANKE, University of Oxford, United Kingdom
SY09.05 Structural topology approaches to define T-cell epitopes
Gaurav GAIHA, Ragon Institute of MGH, MIT and Harvard, United States
SY09.02 Mechanistic insights into prime-boost vaccination
Sandhya VASAN, US Military HIV Research Program, United States
SY09.06 Live Q&A